Skip to content

Effect of therapy reminder application on therapy-adherence

Effect of therapy reminder application on therapy-adherence in adult with Beta thalassemia major patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240222061079N1
Enrollment
80
Registered
2024-03-04
Start date
2024-03-05
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Thalassaemia. Beta thalassemia

Interventions

Intervention 1: Intervention group: Using an offline app for 8 weeks. Intervention 2: Control group: They receive routine treatment without an app.

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1- Patients with thalassemia major aged 18 years and older who have an active file in Sarwar Clinic and are being treated with blood transfusion and iron removal drugs 2- Having an active smartphone that works with the Android operating system, 3- They have sufficient skills in Farsi or English to work with a smartphone and the ability to use it 4- They do not have mental illness and hearing and vision problems (due to hearing and seeing application alarms) 5- Provide written informed consent to participate in the research.

Exclusion criteria

Exclusion criteria: 1- Patients were excluded if they themselves used a medication reminder app or other electronic reminder systems to adhere to their medication regimen, for example calendar alerts on their phones. 2- Patients with smartphones that are unable to download apps are excluded. 3- If a person reports not using the reminder program in two phone calls by the researcher, he will be excluded from the study. 4- Patients who do not want to continue cooperation for any reason will be excluded from the study during the study period.

Design outcomes

Primary

MeasureTime frame
Adherence to treatment. Timepoint: Before and after the intervention (8 weeks apart). Method of measurement: Moriski questionnaire and chronic patient treatment adherence questionnaire.

Secondary

MeasureTime frame
Evaluation of the designed application. Timepoint: Once designed. Method of measurement: Application evaluation questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdieh Arian

Mashhad University of Medical Sciences

arianyem@gmail.com+98 51 3768 9730

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026